Access to basic healthcare for diseases like Sickle Cell Disease (SCD) remains a challenge, particularly for marginalized communities, as highlighted by Suraj’s case. Despite initiatives like the National Sickle Cell Anaemia Elimination Mission, treatment accessibility remains inadequate, with issues like availability of hydroxyurea and blood transfusions persisting. The advent of CRISPR therapies presents promise but also raises questions of equity and access, given the high cost and complex treatment processes. In India, ethical and legal considerations surrounding CRISPR’s medical applications add further complexity. Addressing health disparities and ensuring equitable participation in clinical trials are crucial steps toward providing inclusive healthcare solutions. Ultimately, a comprehensive approach integrating community perspectives is vital for realizing equitable access to treatments like CRISPR therapies, ensuring that individuals like Suraj can access healthcare and live healthier lives.